EP1868601A4 - Mitotische kinesin-hemmer - Google Patents

Mitotische kinesin-hemmer

Info

Publication number
EP1868601A4
EP1868601A4 EP06749225A EP06749225A EP1868601A4 EP 1868601 A4 EP1868601 A4 EP 1868601A4 EP 06749225 A EP06749225 A EP 06749225A EP 06749225 A EP06749225 A EP 06749225A EP 1868601 A4 EP1868601 A4 EP 1868601A4
Authority
EP
European Patent Office
Prior art keywords
inhibitors
mitotic kinesin
kinesin
mitotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06749225A
Other languages
English (en)
French (fr)
Other versions
EP1868601A1 (de
Inventor
Paul J Coleman
Christopher D Cox
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1868601A1 publication Critical patent/EP1868601A1/de
Publication of EP1868601A4 publication Critical patent/EP1868601A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP06749225A 2005-04-07 2006-04-03 Mitotische kinesin-hemmer Withdrawn EP1868601A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66908505P 2005-04-07 2005-04-07
PCT/US2006/012462 WO2006110390A1 (en) 2005-04-07 2006-04-03 Mitotic kinesin inhibitors

Publications (2)

Publication Number Publication Date
EP1868601A1 EP1868601A1 (de) 2007-12-26
EP1868601A4 true EP1868601A4 (de) 2008-12-10

Family

ID=37087336

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06749225A Withdrawn EP1868601A4 (de) 2005-04-07 2006-04-03 Mitotische kinesin-hemmer

Country Status (7)

Country Link
US (1) US7629373B2 (de)
EP (1) EP1868601A4 (de)
JP (1) JP2008535839A (de)
CN (1) CN101155583B (de)
AU (1) AU2006235022B2 (de)
CA (1) CA2602146A1 (de)
WO (1) WO2006110390A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080045492A1 (en) * 2004-12-21 2008-02-21 Coleman Paul J Mitotic Kinesin Inhibitors
MX2009007395A (es) * 2007-01-09 2009-07-17 Bayer Schering Pharma Ag Marcacion radioactiva por fluoracion de aziridinas.
AR068888A1 (es) 2007-10-19 2009-12-16 Schering Corp Derivados de 1, 3, 4 - tiadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la quinesina ksp.
CL2008003062A1 (es) * 2007-11-09 2010-02-19 Schering Corp Compuestos derivados de pirazoles espiro conjugados, inhibidores de la actividad de ksp kinesina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
EP2558452A2 (de) * 2010-04-15 2013-02-20 Novartis AG Oxazol- und thiazolverbindungen als ksp-hemmer
JP2013523867A (ja) * 2010-04-15 2013-06-17 ノバルティス アーゲー Ｋｓｐ阻害剤としてのトリアゾール化合物
WO2012160447A1 (en) 2011-05-25 2012-11-29 Dynamix Pharmaceuticals Ltd. 3, 5 -diphenyl- substituted pyrazolines for the treatment of cancer, proliferative, inflammatory or autoimmune diseases
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003079973A2 (en) * 2002-03-08 2003-10-02 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2006007496A2 (en) * 2004-07-01 2006-01-19 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2006101761A2 (en) * 2005-03-16 2006-09-28 Merck & Co., Inc. Mitotic kinesin inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
CA2294057A1 (en) * 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003079973A2 (en) * 2002-03-08 2003-10-02 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2006007496A2 (en) * 2004-07-01 2006-01-19 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2006101761A2 (en) * 2005-03-16 2006-09-28 Merck & Co., Inc. Mitotic kinesin inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2006110390A1 *

Also Published As

Publication number Publication date
AU2006235022B2 (en) 2011-07-21
AU2006235022A1 (en) 2006-10-19
EP1868601A1 (de) 2007-12-26
JP2008535839A (ja) 2008-09-04
WO2006110390A1 (en) 2006-10-19
CN101155583A (zh) 2008-04-02
CN101155583B (zh) 2011-01-19
CA2602146A1 (en) 2006-10-19
US20090042966A1 (en) 2009-02-12
US7629373B2 (en) 2009-12-08

Similar Documents

Publication Publication Date Title
EP1856128A4 (de) Inhibitoren von mitotischem kinesin
EP1868601A4 (de) Mitotische kinesin-hemmer
EP1656133A4 (de) Inhibitoren von mitotischem kinesin
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
EP1656146A4 (de) Inhibitoren von mitotischem kinesin
EP1656140A4 (de) Inhibitoren von mitotischem kinesin
EP2083864A4 (de) Antagonisten von pcsk9
EP2083859A4 (de) Pcsk9-antagonisten
EP2083860A4 (de) Pcsk9-antagonisten
DK2848610T3 (da) Hæmmere af kinaseaktivitet
CY2013042I2 (el) Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
CY2014011I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DK1898903T3 (da) Inhibitorer af Akt-aktivitet
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
EP1704145A4 (de) Selektive kinaseinhibitoren
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
CR10562A (es) Nuevos derivados de piridazina
DK1916890T3 (da) Forbedrede egenskaber for græsendofytter
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
EP1697331A4 (de) Inhibitoren von mitotischem kinesin
EP1696927A4 (de) Inhibitoren von mitotischem kinesin
EP2032141A4 (de) Januskinase-hemmer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20081110

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/415 20060101AFI20061110BHEP

Ipc: A61P 35/00 20060101ALI20081104BHEP

Ipc: C07D 231/06 20060101ALI20081104BHEP

17Q First examination report despatched

Effective date: 20090202

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERCK SHARP & DOHME CORP.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SCHERING CORPORATION

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERCK SHARP & DOHME CORP.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20131116